Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 1, 2011, Pages 173-185

  Kwekkeboom, Dik J ^a   de Herder, Wouter W ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Gastroenteropancreatic neuroendocrine tumor; Peptide receptor radionuclide therapy; Somatostatin receptor; Targeted radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; PENTETATE INDIUM IN 111; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CREATININE CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; GASTROPANCREATIC NEUROENDOCRINE TUMOR; HAIR LOSS; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETREATMENT; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 79951732688     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.12.003     Document Type: Review

References (46)

1. Krenning E.P., Bakker W.H., Breeman W.A., et al. Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet 1989, 1:242-245.
2. 0]Octreotide: the Rotterdam experience. Semin Nucl Med 2002, 32:110-122.
3. Anthony L.B., Woltering E.A., Espanan G.D., et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002, 32:123-132.
4. Otte A., Herrmann R., Heppeler A., et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999, 26:1439-1447.
5. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941-945.
6. Waldherr C., Pless M., Maecke H.R., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002, 43:610-616.
7. Waldherr C., Schumacher T., Maecke H.R., et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?. Eur J Nucl Med 2002, 29(Suppl 1):S100. [abstract].
8. Chinol M., Bodei L., Cremonesi M., et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 2002, 32:141-147.
9. Paganelli G., Bodei L., Handkiewicz Junak D., et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002, 66:393-398.
10. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003, 30:207-216.
11. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36:147-156.
12. Valkema R., Pauwels S., Kvols L., et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imaging 2003, 30(Suppl 2):S232. [abstract].
13. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003, 44:1556-1560.
14. Bushnell D.L., O'Dorisio T.M., O'Dorisio M.S., et al. 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010, 28:1652-1659.
15. De Jong M., Breeman W.A., Bakker W.H., et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998, 58:437-441.
16. Erion J.L., Bugaj J.E., Schmidt M.A., et al. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model. J Nucl Med 1999, 40(Suppl):223P. [abstract].
17. Reubi J.C., Schaer J.C., Waser B., et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27:273-282.
18. Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001, 28:1319-1325.
19. Esser J.P., Krenning E.P., Teunissen J.J., et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging 2006, 33:1346-1351.
20. 3]octreotate. Eur J Nucl Med Mol Imaging 2003, 30:417-422.
21. 3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol 2005, 23:2754-2762.
22. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
23. De Keizer B., van Aken M.O., Feelders R.A., et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2008, 35:749-755.
24. Teunissen J.J., Kwekkeboom D.J., Krenning E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004, 22:2724-2729.
25. 90Y-DOTA-Lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32:148-155.
26. Wehrmann C., Senftleben S., Zachert C., et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007, 22:406-416.
27. Baum R.P., Soldner J., Schmucking M., et al. Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe 2004, 10:1098-1110. [in German].
28. Baum R.P., Soldner J., Schmucking M., et al. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med 2004, 31(Suppl 2):S238. [abstract].
29. Clancy T.E., Sengupta T.P., Paulus J., et al. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006, 51:877-884.
30. Janson E.T., Holmberg L., Stridsberg M., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997, 8:685-690.
31. Quaedvlieg P.F., Visser O., Lamers C.B., et al. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001, 12:1295-1300.
32. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007, 142:10-19.
33. Van Essen M., Krenning E.P., Kam B.L., et al. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010, 51:383-390.
34. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002, 32:133-140.
35. Wong J.Y., Shibata S., Williams L.E., et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003, 9:5842-5852.
36. Kong G., Lau E., Ramdave S., et al. High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. J Nucl Med 2005, 46(Suppl 2):151P. [abstract].
37. Rich T.A., Shepard R.C., Mosley S.T. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004, 22:2214-2232.
38. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002, 20:3983-3991.
39. Van Essen M., Krenning E.P., Kam B.L., et al. Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35:743-748.
40. McStay M.K., Maudgil D., Williams M., et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005, 237:718-726.
41. Limouris G.S., Chatziioannou A., Kontogeorgakos D., et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008, 35:1827-1837.
42. Kratochwil C., Giesel F.L., López-Benítez R., et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010, 16:2899-2905.
43. Förrer F., Krenning E.P., Kooij P.P., et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009, 36:1138-1146.
44. Valkema R., Pauwels S.A., Kvols L.K., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005, 46(Suppl 1):83S-91S.
45. Bodei L., Cremonesi M., Ferrari M., et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008, 35:1847-1856.
46. Konijnenberg M., Melis M., Valkema R., et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007, 48:134-142.